• Radha K V
  • Lakshmanan D


Cholesterol is an organic compound, which is produced in humans by a complex metabolism. It acts as a precursor for the synthesis of many steroids, vitamin D and also helps in membrane transport. Increase of cholesterol in humans, leads to Cardio Vascular Disorders and finally death. This can be reduced by inhibiting the HMG-CoA reductase, which is an important precursor in formation of mevolanate from Acetyl CoA. Inhibition is done by statin drug, which is produced by many fungi through polyketide pathway. Many fungus produce lovastatin, while other statins like rosuvastatin, simvastatin, pravastatin, fluvastatin are synthesized from lovastatin and mevastatin. Other than reduction of cholesterol, lovastatin is shown to provide various medicinal properties like anti-cancer, bone maturation, multiple sclerosis. In this review, a detailed note on various organisms employed for the production of lovastatin and different fermentation techniques for the same was studied. This review also helps in understating the inhibition of HMG-CoA reducatse and various medicinal properties of lovastatin.

Keywords: Lovastatin, Fungus, Submerged fermentation, Solid state fermentation, HMG-CoA reducatse.


1. Hanukoglu I. Steroidogenic enzymes: structure, function, and role in regulation of steroid hormone biosynthesis. J Steroid Biochem Mol Biol.1992; 43: 779–804.
2. Robert K.Murray, Daryl K. Granner, Peter A.Mayes, Victor W. Rodwell, Cholesterol synthesis, transport and excretion. Peter A.Mayes, Kathleen M.Botham. 26th ed. Mc Graw Hill, 2003, pp 219-241.
3. Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. The Expert Panel. Arch. Intern. Med. 1998; 148: 36–69
4. Brunzell JD, Davidson M, Furberg CD, Goldberg RB, Howard BV, Stein JH, Witztum JL . Lipoprotein management in patients with cardiometabolic risk: consensus statement from the American Diabetes Association and the American College of Cardiology Foundation. Diabetes Care. 2008; 31: 811–22.
5. Kirby. T. J. Cataracts produced by triparanol. (MER-29). Trans. Am. Ophthalmol. Soc.1967; 65, 494–543.
6. Endo A, Kuroda M, Tanzawa K. Competitive inhibition of 3-hydroxy-3-methylglutaryl coenzyme A reductase by ML-562236A and ML-236B fungal metabolites having hypocholesterolemic activity. FEBS Lett. 1976; 72:323–326.
7. Chan JK, Moore RN, Nakashima TT, Vederas JC. Biosyn- thesis of mevinolin. Spectral assignment by double-quantum coherence NMR after high carbon-13 incorporation. J Am Chem Soc. 1983; 105:3334–3336.
8. Moore RN, Bigam G, JK, Hogg AM, Nakashima TT, Vederas JC. Biosynthesis of the hypocholesterolemic agent mevinolin by Aspergillus terreus. Determination of the origin of carbon, hydrogen, and oxygen atoms by 13C NMR and mass spectrometry. J Am Chem Soc. 1985;107:3694–370
9. Shiao M, Don H. Biosynthesis of mevinolin, a hypocholes- terolemic fungal metabolite, in Aspergillus terreus. Proc Natl Sci Counc. 1987; 11:223–231
10. Endo A. Compactin (ML236B) and related compounds as potential cholesterol-lowering agents that inhibit HMG-CoA reductase. J Med Chem. 1985; 28:401–405.
11. Jonathan A.Tobert. Lovastatin and beyond: the history of the hmg-coa reductase inhibitors. Nature review. 2003; 2:517-526.
12. Alberts AW, Chen J, Kuron G, Hunt V, Huff J, Hoffman C. Mevinolin: a highly potent competitive inhibitor of hydroxymethyl glutaryl coenzyme A reductase and cholesterol lowering agent. Proc Natl Acad Sci USA. 1980;77:3957-61.
13. Greenspan MD, Yudrovitz JB. Mevinolinic acid biosynthesis by Aspergillus terreus and its relationship to fatty acid biosynthesis. J Bacteriol. 1985; 162:704–707.
14. Endo A. Monacolin K, a new hypocholesterolemic agent produced by Monascus species. J Antibiot (Tokyo). 1979; 32:852– 854.
15. Endo A. Monacolin K, a new hypocholesterolemic agent that specifically inhibits 3-hydroxy-3-methylglutaryl coenzyme A reductase. J Antibiot (Tokyo). 1980; 33:334–336.
16. Endo A. Microbial phosphorylation of compactin (ML- 236B) and related compounds. J. Antibiot (Tokyo). 1985b; 38:328– 332
17. Komagata D, Shimada H, Murakawa S, Endo A. Biosynthesis of monacolins: conversion of monacolin L to monacolin J by a monooxygenase of Monascus ruber. J Antibiot (Tokyo). 1989; 42:407–412.
18. Negishi S, Cai-Huang Z, Hasumi K, Murakawa S, Endo A. Productivity of monacolin K (mevinolin) in the genus Monascus. J Ferment Eng. 1986; 64:509–512
19. Hosobuchi M, Shiori T, Ohyama J, Arai M, Iwado S, Yoshikawa H. Production of ML-236B, and inhibitor of 3-hydroxy-3- methylglutaryl CoA reductase, by Penicillium citrinum: improvement of strain and culture conditions. Biosci Biotechnol Biochem. 1993; 57:1414–1419.
20. Konya A, Jekkel A, Suto J, Salat J. Optimization of compactin fermentation. J Ind Microbiol Biotechnol. 1998; 20:150– 152.
21. Bazaraa WA, Hamdy MK, Toledo R. Bioreactor for continuous synthesis of compactin by Penicillium cyclopium. J Ind Microbiol Biotechnol. 1998; 2:192–202.
22. Wasser SP, Reshetnikov SV Process for producing, methods and compositions of cholesterol lowering agents from higher basidiomycetes mushrooms. US Patent. 2002; 6: 372 462.
23. Siamak M. Samiee, Nasrin Moazami, Saeid Haghighi, Farzaneh Aziz Mohseni, Saeid Mirdamadi and Mohammad Reza Bakhtiari. Screening of Lovastatin Production by Filamentous Fungi. Iran Biomed J. 2003; 7: 29-33.
24. Vilches Ferro´n M.A., Casas Lo´pez J.L,. Sa´nchez Pe´rez J.A, Ferna´ndez Sevilla J.M. and Chisti Y. Rapid screening of Aspergillus terreus mutants for overproduction of lovastatin. World J Microb Biot. 2005; 21: 123–125.
25. Srinu M, Phani G.V. Bhusha N., Feleke moges, Srilakshmi J, Sankar G, Prabhakar T, Lakshminarayana K. Screening of Hmg Co A Reductase Inhibitor producing Marine Actinomycetes. JPRHC. 2010; 2: 66-74.
26. Sree Devi K, Venkateswara Rao J, Lakshmi Narasu M, SaiKrishna K. Isolation and screening of lovastatin producing Aspergillus terreus fungal strains from soil samples. IJPT. 2011; 3: 2772-2782.
27. Manzoni M, Rollini M. Biosynthesis and biotechnological production of statins by filamentous fungi and application of these cholesterol-lowering drugs. Appl Microbiol Biotechnol. 2002; 58:555-64.
28. Buckland B, Gbewonyo K, Hallada T, Kaplan L, Masurekar P. Production of lovastatin, an inhibitor of cholesterol ac- cumulation in humans. In: Demain AL, Somkuti GA, Hunter- Cevera JC, Rossmore HW (eds) Novel microbial products for medicine and agriculture. Elsevier, Amsterdam. 1989; 161–169.
29. Osman M.E.,. Khattab O.H,. Zaghlol G.M, Rehab. M. Abd El-Hameed. Optimization of Some Physical and Chemical Factors for Lovastatin Productivity by Local Strain of Aspergillus terreus, Aust J Basic and Appl Sci. 2011; 5: 718-732.
30. Casas Lo´pez JA , Sa´nchez Pe´rez JA, Ferna´ndez Sevilla JM, Acie´n Ferna´ndez FG, Molina Grima and Chisti Y. Production of lovastatin by Aspergillus terreus: Effects of the C:N ratio and the principal nutrients on growth and metabolite production. Enzyme Microb Tech.2003;33:270–277.
31. Casas Lo´pez JL, Sa´nchez Pe´rez JA, Ferna´ndez Sevilla JM, Acie´n Ferna´ndez FG, Molina Grima E and Chisti Y. Fermentation optimization for the production of lovastatin by Aspergillus terreus: use of response surface methodology. J Chem Technol Biotechnol. 2004; 79:1119–1126.
32. Elisa M Rodr´ıguez Porcel, Jose L Casas Lo´pez, Jose A Sa´nchez Pe´rez and Yusuf Chisti; Lovastatin production by Aspergillus terreus in a two-staged feeding operation. J Chem Technol Biotechnol. 2008; 83:1236–1243.
33. Sreedevi K, VenkateswaraRao J, Lakshmi Narasu and Fareedullah Md. Strain improvement of Aspergillus terreus for the enhanced production of lovastatin, a HMG-COA reductase inhibitor; J. Microbiol. Biotech. Res. 2011; 1:96-100.
34. Novak N, Gerdin S, Berovic M. Increased lovastatin formation by Aspergillus terreus using repeated fed-batch process. Biotechnol Lett .1997; 19:947-948.
35. Sitaram Kumar M, Swapan K. Jana, Senthil V, Shashanka V, Vijay Kumar S, Sadhukhan AK. Repeated fed-batch process for improving lovastatin production. Process Biochem.2000; 36: 363–368.
36. Pattana Sripalakit , Janya Riunkesorn and Aurasorn Saraphanchotiwitthaya. Utilisation of vegetable oils in the production of lovastatin by Aspergillus terreus ATCC 20542 in submerged cultivation. Maejo Int. J. Sci. Technol. 2011; 5: 231-240.
37. Long-Shan T. Lai, Tai-Her Tsai, and Te Chi Wang. Application of Oxygen Vectors to Aspergillus terreus Cultivation. J Biosci Bioeng. 2002; 94:453-459.
38. Kamakshi Gupta, Bodhisatta Maiti, P K Mishra, Pradeep Srivastava. Fuzzy rule-based prediction of lovastatin productivity in continuous mode using pellets of Aspergillus terreus in an airlift reactor. J Biochem Tech. 2009; 2:138-143
39. Marcin Bizukojc, Stanislaw Ledakowicz. Simultaneous biosynthesis of (+)-geodin by a lovastatin-producing fungus Aspergillus terreus. J Biotechnol.2007; 132:453–460.
40. Tsuyoshi Miyake, Kumiko Uchitomi, Ming-Yong Zhang; Nobuyuki Nozaki, Hiroyuki Sammotoand Kenji INAGAKI. Effects of the Principal Nutrients on Lovastatin Production by Monascus pilosus. Biosci. Biotechnol. Biochem.2006;70: 1154–1159.
41. Sadik Ali Sayyad & Bibhu Prasad Panda & Saleem Javed & Mohd Ali. Optimization of nutrient parameters for lovastatin production by Monascus purpureus MTCC 369 under submerged fermentation using response surface methodology. Appl Microbiol Biotechnol. 2007; 73:1054–1058
42. Subhagar Seraman, Aravindan Rajendran, Viruthagiri Thangavelu. Statistical optimization of anticholesterolemic drug lovastatin production by the red mold Monascus purpureus. Food Bioprod Process. 2010; 88:266–276.
43. Chung C.C, Chen H.H. and Hsieh. P.C. Application of the taguchi method to optimize monascus spp. Culture. J Food Process Eng.2007; 30: 241–254.
44. Pandey A, Soccol CR, Rodrigoez-Leon and Nigam P. Solid state fermentation in biotechnology- Fundamentals and Applications Ist ed. New Delhi India: Asiatech Publications Inc 2001
45. Praveen, Savitha, J ; Solid State Fermentation: An Effective Method for Lovastatin Production by Fungi – A Mini Review. The Open Tropical Medicine Journal. 2012; 5:1-5.
46. Jaivel N and Marimuthu P. Optimization of lovastatin production in solid state fermentation by Aspergillus terreus. Int J Eng Sci Technol.2010; 2: 2730-2733.
47. Ruchir C. Pansuriya; Rekha S. Singhal; response surface methodology for optimization of production of lovastatin by solid state fermentation. Braz J Microbiol. 2010; 41: 164-172.
48. Pallem akya, Parvatham Madhu Latha , Manipati Srikanth; Solid state fermentation for the production of lovastatin by Aspergillus fischeri. Res J Pharm Sci Biotech. 2011;1:9-13.
49. Sri Rami Reddy D, Prasanna Latha D, Hema Latha KPJ. Production of Lovastatin by Solid State Fermentation by Penicillium Funiculosum NCIM 1174. Drug Invention Today. 2011; 3: 75- 77.
50. Valera H.R., Gomes J., Lakshmi S., Gurujara Ra., Suryanarayan S., Kumar D. Lovastatin production by solid state fermentation using Aspergillus flavipes. Enz. Microbiol. Technol. 2005; 37: 521-526.
51. Lakshmanan D and Radha K.V; An effective quantitative estimation of lovastatin from Pleurotus ostreatus using UV and HPLC. Int J Pharm Pharm Sci.2012; 4: 462-464.
52. Rizna Triana Dewi, Nina Artanti, Hani Mulyani, Puspa Dewi Narrij Lotulung, and Minarti; Production of lovastatin and sulochrin by Aspergillus terreus using solid state fermentation; Makara, Teknologi. 2011;15:1-4.
53. Geeta Aparna D and Sri Rami Reddy D. Production of lovastatin by Aspergillus parasiticus NCIM 696 using rice bran under solid state fermentation. J. Chem. Bio. Phy. Sci. Sec. B. 2011; 2: 284-291.
54. Seraman Subhagar Rajendran Aravindan Thangavelu Viruthagir. Response surface optimization of mixed substrate solid state fermentation for the production of lovastatin by Monascus purpureus. Eng. Life Sci. 2009; 9: 303–310.
55. Bibhu Prasad Panda, Saleem Javed and Mohamed Ali; Engineering rice based medium for production of lovastatin with Monascus Species. Czech J. Food Sci. 2009; 27:352–360.
56. Panda BP, Javed S, Ali M. Statistical analysis and validation of process parameters influencing lovastatin production by Monascus purpureus MTCC 369 under solid state fermentation. Biotechnol Bioprocess Eng. 2009; 14: 123-7.
57. Prabhakar M. Lingappa K. Vivek babu. Amena S. Vishalakshi N. AND Mahesh D. Characterization of physical factors for optimum lovastatin production by Aspergillus terreus KLVB28mu21 under solid state fermentation. JRAAS. 2012; 27:01-05.
58. Barrios G, Barrios JG, Covarrubias AA, Arroyo AG. Lovastatin biosynthetic genes are expressed differentially in solid state and in liquid submerged fermentation. Appl Microbiol Biotechnol 2008; 79:179-86.
59. Gibbons RJ, Abrams J, Chatterjee K, Daley J, Deedwania PC, Douglas JS. ACC/ AHA 2002 guideline update for the management of patients with chronic stable angina – summary article: A report of the American College of Cardiology/ American Heart Association Task Force on practice guidelines. J Am Coll Cardiol. 2003;41:159-68.
60. Seenivasan, Subhagar S., Aravindan R. And Viruthagir. T. Microbial Production and Biomedical Applications of Lovastatin. Indian J Pharm Sci. 2008;70:701-709.
61. Pickin DM, McCabe CJ, Ramsay LE, Payne N, Haq IU, Yeo WW. Cost effectiveness of HMG-CoA reductase inhibitor (statin) treatment related to the risk of coronary heart disease and cost of drug treatment. Heart. 1999;82:325-32.
62. Alberts AW, Chen J, Kuron G, Hunt V, Huff J, Hoffman C, Rothrock J, Lopez M, Joshua H, Harris E, Patchett A, Monaghan G, Currie S, Stapley E, Albers-Schonberg G, Hensens O, Hirshfield J, Hoogsteen K, Liesch J. Mevinolin: a highly potent competitive inhibitor of hydroxymethylglutaryl-coenzyme A reductase and cholesterol lowering agent. Proc Natl Acad Sci USA.1980; 77:3957–3961.
63. Eckert GP, Wood WG, Muller WE. Statins: Drugs for Alz-heimer’s disease?. J Neural Transm. 2005; 112: 1057-71.
64. Ohm TG, Meske V. Cholesterol, statins and tau. Acta Neurol Scand. 2006;114:93-101.
65. Zamvil SS, Steinman L. Cholesterol-lowering statins possess anti- inflammatory activity that might be useful for treatment of MS. Neurology. 2002; 59: 970-1.
66. Buemi M, Senator M, Corica f. Satins and progressive renal disease. Med Res Rev. 2002; 22: 76-84.
67. Garrett IR, Gutierrez GE, Rossini G, Nyman J, McCluskey B, Flores A, Mundy GR. Locally delivered lovastatin nanoparticles enhance fracture healing in rats. J. Ortho. Res. 2007; 25: 1351-1357.
68. Tandon V, Bano G, Khajuria V, Parihar A, Gupta S. Pleiotropic effects of statins. Ind J Pharmacol. 2005; 37: 77-85.
69. Glynn SA, O'Sullivan D, Eustace AJ, Clynes M, O'Donovan N. The 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors, simvastatin, lovastatin and mevastatin inhibit proliferation and in- vasion of melanoma cells. BMC Cancer. 2008; 16: 8-9.
70. Xia Z, tan MM, Wing WW, Dimitroulakos J, Minden MD, Penn LZ. Blocking protein geranylgeranylazation is essential for lovastatin induced apoptosis of human acute myeloid leukemia cells. Leukem.2001; 15: 1398-407.
4141 Views | 961 Downloads
How to Cite
K V, R., and L. D. “A REVIEW: LOVASTATIN PRODUCTION AND APPLICATIONS”. Asian Journal of Pharmaceutical and Clinical Research, Vol. 6, no. 3, July 2013, pp. 21-26, https://innovareacademics.in/journals/index.php/ajpcr/article/view/173.